Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma
eLife · 2023
DOI: 10.7554/elife.76294 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Anthony Lozano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Génétique Moléculaire de Montpellier, University of Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SIRIC Montpellier Cancer, Grant HTE-ITMO Cancer, Association Francaise pour l'Etude du Foie.
Abstract (Originalsprache)
Quantitative differences in signal transduction are to date an understudied feature of tumour heterogeneity. The MAPK Erk pathway, which is activated in a large proportion of human tumours, is a prototypic example of distinct cell fates being driven by signal intensity. We have used primary hepatocyte precursors transformed with different dosages of an oncogenic form of Ras to model subclonal variations in MAPK signalling. Orthotopic allografts of Ras-transformed cells in immunocompromised mice gave rise to fast-growing aggressive tumours, both at the primary location and in the peritoneal cavity. Fluorescent labelling of cells expressing different oncogene levels, and consequently varying levels of MAPK Erk activation, highlighted the selection processes operating at the two sites of tumour growth. Indeed, significantly higher Ras expression was observed in primary as compared to secondary, metastatic sites, despite the apparent evolutionary trade-off of increased apoptotic death in the liver that correlated with high Ras dosage. Analysis of the immune tumour microenvironment at the two locations suggests that fast peritoneal tumour growth in the immunocompromised setting is abrogated in immunocompetent animals due to efficient antigen presentation by peritoneal dendritic cells. Furthermore, our data indicate that, in contrast to the metastatic-like outgrowth, strong MAPK signalling is required in the primary liver tumours to resist elimination by NK (natural killer) cells. Overall, this study describes a quantitative aspect of tumour heterogeneity and points to a potential vulnerability of a subtype of hepatocellular carcinoma as a function of MAPK Erk signalling intensity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, Montpellier, France.
- Department of surgery and liver transplantation, Hopital Saint Eloi Hopitaux universitaires de Montpelier, Montpellier, France.
- Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, Netherlands.
- Centre de Recherche en Biologie Cellulaire de Montpellier (CRBM), University of Montpellier, CNRS, Montpellier, France.
ORCID-Profile: Philippe Fort, Damien Grégoire
Förderung
- SIRIC Montpellier Cancer
- Grant HTE-ITMO Cancer
- Association Francaise pour l'Etude du Foie
- KWF Kankerbestrijding
Zitieren
APA
Lozano, A., Souche, F. R., Chavey, C., Dardalhon, V., Ramirez, C., Vegna, S., Desandre, G., Riviere, A., Zine El Aabidine, A., Fort, P., Akkari, L., Hibner, U., & Grégoire, D. (2023). Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma. eLife. https://doi.org/10.7554/elife.76294
Vancouver
Lozano A, Souche FR, Chavey C, Dardalhon V, Ramirez C, Vegna S, et al. Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma. eLife. 2023. doi:10.7554/elife.76294
BibTeX
@article{Lozano2023,
author = {Lozano, Anthony and Souche, Francois-Régis and Chavey, Carine and Dardalhon, Valérie and Ramirez, Christel and Vegna, Serena and Desandre, Guillaume and Riviere, Anaïs and Zine El Aabidine, Amal and Fort, Philippe and Akkari, Leila and Hibner, Urszula and Grégoire, Damien},
title = {Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.76294}
}
EUVIMED